Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease

A 10-week placebo-controlled double-blind crossover protocol of combination therapy with lecithin and ergoloid mesylates was conducted in seven patients with presenile and senile dementia, Alzheimer's type. The patients' abilities to detect spatial arrangements, to recognize faces, and to identify new words on the Delayed Recognition Span Test were not significantly improved. Dementia Rating Scale scores before treatment were not significantly different from those after treatment.